Literature DB >> 1683122

RGD-containing peptides of VP1 of foot-and-mouth disease virus (FMDV) prevent virus infection in vitro.

H Liebermann1, R Dölling, D Schmidt, G Thalmann.   

Abstract

RGD-containing peptides from the immunodominant region of VP1 between amino acids 135-160 from foot-and-mouth disease virus (FMDV) type O1 Kaufbeuren (O1K) prevented virus adsorption to piglet kidney (PK) cells. The highly conserved amino acid RGD sequence (Arg.-Gly.-Asp.) was a prerequisite of this effect. To prevent infection with 100-200 TCID50 in 10(6) PK cells, 20-250 micrograms of each peptide should have been added.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1683122

Source DB:  PubMed          Journal:  Acta Virol        ISSN： 0001-723X            Impact factor:   1.162


  12 in total

1.  The foot and mouth disease virus type O outbreak of 1992 is not related to vaccine strain (O/R2/75).

Authors:  V Suryanarayana; P Tulasiram; K S Prabhudas; L D Misra; C Natarajan
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

2.  Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes.

Authors:  L A Lagenaur; J M Palefsky
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

3.  Cellular DNAJA3, a Novel VP1-Interacting Protein, Inhibits Foot-and-Mouth Disease Virus Replication by Inducing Lysosomal Degradation of VP1 and Attenuating Its Antagonistic Role in the Beta Interferon Signaling Pathway.

Authors:  Wei Zhang; Fan Yang; Zixiang Zhu; Yang Yang; Zhifang Wang; Weijun Cao; Wen Dang; Linlin Li; Ruoqing Mao; Yongjie Liu; Hong Tian; Keshan Zhang; Xiangtao Liu; Junwu Ma; Haixue Zheng
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

4.  Monoclonal and polyclonal antibodies specific for foot and mouth disease virus type A and type O VP1.

Authors:  Jin Gu Cho; Yeong Joon Jo; Jong-Hyuk Sung; Jang-Kwan Hong; Ji-Hyeon Hwang; Jong-Hyeon Park; Kwang-Nyeong Lee; Sang Gyu Park
Journal:  Hybridoma (Larchmt)       Date:  2012-10

5.  EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.

Authors:  Jianqiao Xiao; Joel M Palefsky; Rossana Herrera; Carl Sunshine; Sharof M Tugizov
Journal:  Virology       Date:  2009-08-20       Impact factor: 3.616

6.  Receptor binding sites and antigenic epitopes on the fiber knob of human adenovirus serotype 3.

Authors:  H Liebermann; R Mentel; U Bauer; P Pring-Akerblom; R Dölling; S Modrow; W Seidel
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Macrophage phagocytosis of foot-and-mouth disease virus may create infectious carriers.

Authors:  Rachael C Rigden; Carlos P Carrasco; Artur Summerfield; Kenneth C MCCullough
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

8.  Genome variation in the SAT types of foot-and-mouth disease viruses prevalent in buffalo (Syncerus caffer) in the Kruger National Park and other regions of southern Africa, 1986-93.

Authors:  W Vosloo; E Kirkbride; R G Bengis; D F Keet; G R Thomson
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

9.  Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for alphav integrins.

Authors:  Alison Burman; Stuart Clark; Nicola G A Abrescia; Elizabeth E Fry; David I Stuart; Terry Jackson
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

10.  Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection.

Authors:  Terry Jackson; Stuart Clark; Stephen Berryman; Alison Burman; Stephanie Cambier; Dezhi Mu; Stephen Nishimura; Andrew M Q King
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.